Key Highlights
- Odyssey Therapeutics shares were trading down 9.27% at $19.57, against a prior close of $21.57.
- The third-quarter net loss was $53.1 million, or $1.10 per share.
- Cash of $387 million is expected to fund operations into the second half of 2028.
- A lock-up covering roughly 30.4 million shares is ending.
- OD-001 Phase 2b topline data are expected in the second half of 2027.
Lock-Up Expiry and a Wider Loss Pressure the Shares
Odyssey Therapeutics (NASDAQ:ODTX) shares were trading down 9.27% at $19.57 on Wednesday, on Volume well above average, after closing up 10.5% in the prior session. The end of a lock-up covering roughly 30.4 million shares may add Supply pressure, and the stock moved lower against a strong health sector.
The company reported a third-quarter net loss of $53.1 million, or $1.10 per share, against $35.5 million a year earlier.
OD-001 Strengthens the Ulcerative Colitis Case
Odyssey presented more Phase 2a data for OD-001, an oral RIPK2 scaffolding inhibitor, covering 56 efficacy-evaluable patients with moderate-to-severe ulcerative colitis. The company says clinical results are supported by matching biomarker and transcriptomic findings. A Phase 2b monotherapy trial and a combination trial are planned, with Phase 2b topline data expected in the second half of 2027.
Pipeline Beyond the Lead
OD-002, an oral SLC15A4 inhibitor, completed IND-enabling studies and is expected to enter Phase 1/2a in the first quarter of 2027. Preclinical data for OD-003, a TNFR2 agonist, will be presented at the American College of Rheumatology meeting from November 6 to 11. The pipeline also includes a TSLP and IL-33 bispecific antibody.
Funding and Spending Trends
Research and development spending rose to $42.1 million, and cash, equivalents and marketable securities were $387 million at the end of September, enough to fund operations into the second half of 2028. The company is pre-revenue, and the stock sits between its 52-week low of $15.10 and high of $29.05.






Please wait processing your request...